MygoGenesis unveils white paper on patient-derived Mygotes for regenerative medicine

By AI, Created 2:16 PM UTC, June 04, 2026, /AGP/ – MygoGenesis published a white paper introducing Mygotes, autologous embryonic-like cells made through its Mygotic Process for regenerative medicine, cell therapy and biomanufacturing. The company says the platform is designed to avoid viral vectors, genetic engineering and conventional iPSC reprogramming while aiming to improve scalability and cell quality.

Why it matters: - MygoGenesis is pitching Mygotes as a new starting cell for regenerative medicine, where the quality of the source cell can shape safety, reliability, scalability and clinical use. - The company is positioning the platform against embryonic stem cells and iPSCs, two approaches that have faced ethical, regulatory, technical or manufacturing limits. - The white paper argues that a non-genetic, patient-derived cell source could widen applications in blood, cardiac, neural, pancreatic, kidney and cartilage development.

What happened: - MygoGenesis on June 4, 2026, announced a new white paper introducing Mygotes, patient-derived cells generated through the company’s proprietary Mygotic Process. - The paper describes Mygotes as autologous, laboratory-produced, embryonic-like developmental-state cells for regenerative medicine, cell therapy, tissue engineering and biomanufacturing. - The white paper is titled “Autologous Mygotic Cells as Totipotent/Pluripotent Stem Cells: Overcoming iPSC Limitations and Generating All Three Lineages.” - The company said the white paper is available for download at More information.

The details: - MygoGenesis says the Mygotic Process restores patient-derived somatic cells to a more plastic, early developmental state without forcing adult cells backward through genetic or viral reprogramming. - The company says Mygotes are produced without viral vectors, vector-based manipulation, genetic engineering or forced transcription-factor reprogramming. - The paper says Mygotes express pluripotency-associated markers including Sox2, Oct4, Nanog, SSEA-4, TRA-1-60 and TRA-1-81. - The paper says Mygotes can generate cell types across all three germ-layer lineages. - The company says Mygotes are produced on faster timelines than conventional iPSC workflows. - The platform is intended as a starting cell for blood, cardiac, neural, pancreatic, kidney, cartilage and other cell and tissue applications. - The white paper presents a proof-of-science in which MygoGenesis generated hematopoietic progenitor cells and terminally differentiated red blood cells from fibroblasts through the Mygotic Process. - The company says those data support Mygotes as a platform for autologous blood-cell generation, regenerative medicine and scalable cell manufacturing.

Between the lines: - MygoGenesis is challenging a core assumption in the field: that iPSCs are the best bridge between adult cells and therapeutic cell development. - Daniel Kilbank, corresponding author and co-founder and CSO, said the field needs a better starting cell, not just better differentiation protocols. - Deborah Zimmermann, president and CEO, said Mygotes are meant to provide a natural, patient-derived, embryonic-like foundation without the embryo and without iPSC engineering. - The messaging suggests MygoGenesis wants to frame its platform as a manufacturing advance as much as a biology advance.

What’s next: - MygoGenesis said the white paper is part of a broader publication series. - The company plans a follow-up paper focused on the Mygotic Process, including its mechanism, developmental stages, platform implications and applications across therapeutic development and biomanufacturing. - The company is also promoting the platform through its public channels, including its LinkedIn page.

The bottom line: - MygoGenesis is betting that regenerative medicine needs a new source cell, not just a new reprogramming workflow.